Thrombovazim 400 IU 50 capsules

As an adjunctive treatment in the comprehensive therapy of chronic venous insufficiency.

The medication is taken orally 30-40 minutes before meals at a dosage of 800-1600 IU per day, divided into two doses. The maximum daily dose is 2000 IU. The treatment course lasts 20 days. If there is no effectiveness during the treatment course, consult a doctor. If necessary, repeated courses may be conducted upon a doctor's recommendation.

One capsule contains:
Active ingredient - Thrombovazim® 400 IU,
Excipients:
Potato starch 0.261 g,
Microcrystalline cellulose 0.120 g,
Sodium chloride 0.009 g
The gelatin capsule contains:
Colorants: Azorubine E 122, Patent Blue V E 131, Titanium dioxide E 171, Gelatin.

Hard gelatin capsules No. 0 with a white body and a dark pink cap, printed in white with "TROMBOVAZIM®". The contents of the capsule are a powder ranging from white with a yellowish-brown tint to light brown.

• increased sensitivity to the drug;

• pregnancy;

• lactation;

• age under 18 years (efficacy and safety not established);

• peptic ulcer disease of the stomach and duodenum (during exacerbation);

• simultaneous use with medications containing salts of divalent metals (calcium, magnesium, zinc, iron) and tetracycline antibiotics (tetracycline, chlortetracycline hydrochloride, and oxytetracycline hydrochloride).

POSSIBILITIES AND FEATURES OF USE DURING PREGNANCY AND LACTATION
The drug is contraindicated for use during pregnancy and lactation.

PRECAUTIONS WHEN TAKING

• polyvalent allergy;

• chronic obstructive pulmonary disease;

• risk of bleeding from esophageal veins;

• urolithiasis;

• peptic ulcer disease of the stomach and duodenum (in remission).

INFLUENCE ON THE ABILITY TO DRIVE VEHICLES AND OPERATE MACHINERY
Studies on the possible influence of the drug on the ability to drive vehicles and operate machinery have not been conducted, as the drug and its components are not substances that can affect a person's psychomotor state.

Allergic reactions may occur; in rare cases, dyspeptic symptoms (nausea, vomiting, feeling of heaviness in the stomach) may be observed. A temporary feeling of fullness in the lower extremities is possible.

No cases of overdose have been observed.

Heparin, dipyridamole, acetylsalicylic acid enhance the antithrombotic effect without increasing the risk of bleeding. The use of antibiotics from the tetracycline group (tetracycline, chlortetracycline hydrochloride, and oxytetracycline hydrochloride) enhances the effect of fibrinolytics. If it is necessary to use preparations containing salts of divalent metals (calcium, magnesium, zinc, iron), it is advisable to maintain an interval of at least 40 minutes between the administration of Trombozavim® and the mentioned preparations due to the possible reduction in enzyme activity.

The drug has thrombolytic, anti-inflammatory, and cardioprotective effects.
Pharmacodynamics
The mechanism of thrombolytic action is associated with the direct destruction of fibrin strands that form the main framework of the thrombus. The mechanism of anti-inflammatory action is related to the influence on the oxidative function of blood neutrophils and tissue macrophages. The mechanism of cardioprotective action is associated with the improvement of myocardial blood supply. Thrombozime® is a low-toxicity drug. Thrombozime® does not reduce platelet levels and does not affect coagulation time or the duration of bleeding.

The bioavailability of the drug when taken orally is 16%-18%. Maximum effect occurs after 6 hours. The total clearance is 1.2 ml/min, and the elimination rate constant after a single dose is 0.057 min-1. The half-life of the drug, measured by specific activity in the blood, is 12 minutes. It does not bind to plasma proteins and formed elements. It does not accumulate in the body when recommended doses and frequency of administration are followed. The primary route of elimination is through the kidneys (80%). It is partially metabolized and excreted by the liver (about 20%).

Thrombovazim is a medication designed for the prevention and treatment of various diseases related to impaired blood circulation, exhibiting thrombolytic, anti-inflammatory, and cardioprotective effects. It comes in capsules containing 400 IU of the active ingredient Thrombovazim. It is recommended as an adjunctive treatment in the comprehensive therapy of chronic venous insufficiency.

The mechanism of the thrombolytic action of Thrombovazim is associated with the direct destruction of fibrin strands, which form the main framework of the thrombus. The mechanism of the anti-inflammatory action is related to its effect on the oxidative function of blood neutrophils and tissue macrophages. The mechanism of the cardioprotective action is associated with the improvement of myocardial blood supply.

The medication is taken orally 30-40 minutes before meals at a dosage of 800-1600 IU per day, divided into two doses.

It is recommended to consult a doctor before use.